Close Menu

NEW YORK – Agios Pharmaceuticals said on Monday that its Phase III ClarIDHy trial did not demonstrate a statistically significant survival advantage for ivosidenib (Tibsovo) in patients with IDH1-mutated cholangiocarcinoma compared to placebo.

The ClarIDHy has already met its primary endpoint by demonstrating that patients with IDH1-mutated tumors on ivosidenib had a median progression-free survival of 2.7 months compared to 1.4 months on placebo. 

To read the full story....

...and receive Weekly News bulletins.

Already have a Precision Oncology News or 360Dx or GenomeWeb account?
Login Now.

Don't have a Precision Oncology News or 360Dx or GenomeWeb account?
Register for Free.

Apr
27
Sponsored by
Biognosys

This webinar, the first in our Next-Generation Proteomics for Precision Oncology series, will discuss how proteomics can help overcome the challenges of treating COVID-19 patients with oncologic comorbidities.

Jun
16
Sponsored by
Biognosys

This webinar, the second in our Next-Generation Proteomics for Precision Oncology series, will discuss how unbiased discovery proteomics can be used to identify new key mechanisms and signatures supporting clinical decision-making for melanoma patients.

Jun
18
Sponsored by
Canexia Health

Last year, by Precision Oncology News' count, the FDA approved 27 precision oncology drugs, a 35 percent increase in the number of approvals from 2019.